Apellis (APLS) Q4 2025 earnings review
EMPAVELI Shines While SYFOVRE Free-Goods Drag Masks Volume Growth
Apellis delivered a mixed Q4. The EMPAVELI franchise accelerated, with Q4 revenue surging 50% YoY to $35.1M on the back of a highly successful launch in C3G and primary IC-MPGN. Conversely, the flagship SYFOVRE franchise saw its revenue trajectory reversing, dropping 7.5% YoY to $155.2M. Strikingly, this revenue decline occurred despite a 17% YoY increase in total SYFOVRE injections—a divergence driven by heavy reliance on free goods (13K doses in Q4) to bridge gaps in patient co-pay assistance. While a $275M one-time royalty buyout from Sobi pushed the company into full-year profitability, the core operating loss actually widened in Q4 to $59M as SG&A expenses surged. Management projects cash runway to profitability, but this relies heavily on stabilizing SYFOVRE's gross-to-net dynamics in 2026.
🐂 Bull Case
The C3G/IC-MPGN launch exceeded expectations, achieving >5% US market penetration in just five months with 267 start forms. Q4 sales grew 50% YoY, proving Apellis can effectively execute in rare nephrology.
Despite the revenue decline, actual injection volumes for SYFOVRE grew 17% YoY. The company maintains a dominant 60% market share in GA, supported by new 5-year GALE data showing increasing treatment effects.
🐻 Bear Case
Volume growth is useless if it cannot be monetized. With 13% of Q4 doses given away as free goods and 2026 gross-to-net guided to worsen into the 'high 20% range', the revenue ceiling for SYFOVRE is lowering.
Q4 SG&A spiked 21% YoY to $147M, drastically outpacing total product revenue decline. The company had to pump $34M into patient assistance organizations to prop up access, destroying quarterly operating margins.
⚖️ Verdict: 🔴
Bearish. The EMPAVELI turnaround is impressive, but Apellis is fundamentally valued on SYFOVRE. A situation where a blockbuster-hopeful drug sees volume rise 17% but revenue fall 7.5% due to systemic co-pay and access issues is a major red flag for near-term cash generation.
Key Themes
Data Contradiction: Volume Up, Revenue Down
Management's narrative highlighted that 'SYFOVRE continues to be a resilient and durable business' with a 17% growth in total injections. However, the data contradicts the financial resilience of this growth: Q4 SYFOVRE revenue actually fell from $167.8M in 24Q4 to $155.2M in 25Q4. Apellis delivered 102K doses, but 13K (approx. 13%) were free goods. Giving away the drug to maintain market share severely damages unit economics.
EMPAVELI Nephrology Launch Accelerating
EMPAVELI's expansion into C3G and primary IC-MPGN is performing exceptionally well. Revenue accelerated from $23.4M in 24Q4 to $35.1M in 25Q4. Apellis secured 267 cumulative start forms by year-end, representing over 5% penetration of the estimated 5,000-patient US market in just its first full quarter post-launch. Payer access is remarkably strong, with 95% of policies covering to label.
Pre-Filled Syringe (PFS) Nearing Submission
A critical lifecycle management catalyst is approaching: Apellis plans to submit for regulatory approval of a SYFOVRE prefilled syringe in 1H 2026. This practice-enabling innovation eliminates the current cumbersome process of drawing the drug from a vial through a filter needle, vastly improving workflow efficiency in busy retina clinics. This could serve as a major defensive moat to retain their 60% market share against encroaching competitors.
Macro Headwind: Co-Pay Assistance System Failures
Apellis is suffering from a systemic macro issue: funding gaps at independent non-profit co-pay assistance organizations. When these third-party programs ran out of funding, Medicare patients couldn't afford SYFOVRE. Apellis was forced to bridge the gap with free drug samples to prevent workflow disruptions and patient drop-offs. While funds are beginning to reopen in early 2026, the structural fragility of US Medicare patient access for expensive specialty drugs remains a persistent threat to Apellis's top line.
SG&A Surge Driven by Subsidy Requirements
Selling, General and Administrative expenses are accelerating at an unsustainable rate compared to revenue. Q4 SG&A jumped 21% YoY to $147.1M. For the full year, SG&A was $550.3M. Management explicitly noted this was driven by $34M in contributions to patient assistance organizations (with $21.5M paid in Q4 alone for 2026 support). Essentially, Apellis is having to heavily subsidize the ecosystem to keep patients on therapy.
Next-Generation Pipeline Progressing (APL-3007 & OCT-F)
Apellis is investing in technological evolution to stay ahead in GA. They have advanced OCT-F (Optical Coherence Tomography - Functional), an AI imaging tool to visualize functional decline, expected for research use in 2H 2026. Therapeutically, the Phase 2 trial combining SYFOVRE with APL-3007 (an siRNA therapy showing >90% systemic C3 knockdown) is underway, aiming to completely block complement activity in both the retina and choroid.
Other KPIs
Reversing. The company swung from an operating cash burn of $87.9M in FY24 to positive $45.3M in FY25. However, this is heavily skewed by a one-time $275M upfront payment from Sobi for a royalty buy-down. Without this non-recurring capital injection, the underlying business burned over $200M in cash. Cash balance remains healthy at $466M.
Accelerating. Up significantly from $71.4M in FY24. While the bulk of the increase is the $275M royalty buy-down modification, Sobi also triggered a $25M milestone (paid in Feb 2026) for the European approval of Aspaveli in C3G/IC-MPGN. However, moving forward, ongoing royalty rates from Sobi are reduced by 90% until a specific sales cap is hit, which will suppress recurring ex-US revenue.
Guidance
Decelerating profitability. Management expects gross-to-net deductions to increase from the 'mid-20% range' seen in Q4 2025 to the 'high 20% range' in 2026. This is attributed to the normal step-wise evolution of the buy-and-bill market, meaning Apellis will keep a smaller percentage of the drug's list price.
Decelerating. Management warned of a modest inventory reduction in the channel alongside typical seasonal dynamics (Medicare re-verifications and winter weather). They expect Q1 to be the softest quarter of the year, echoing the Q1 2025 dynamic, leading to relatively flat overall revenue expectations for FY26 compared to FY25.
Accelerating costs. Despite SG&A efficiency optimization, overall OpEx will rise due to incremental R&D investments. Apellis recently initiated two new pivotal Phase 3 trials for EMPAVELI in FSGS and DGF, which will drive clinical trial expenses higher throughout the year.
Key Questions
Path to Profitability Reality
You maintain that current cash will fund operations to profitability. However, FY25 cash flow was only positive due to the $275M Sobi buyout, and SYFOVRE revenue is currently flat-to-down YoY. What is the structural bridge to positive operating cash flow excluding one-time partnership payments?
Free Goods and Co-Pay Dynamics
With 13% of Q4 SYFOVRE volume distributed as free goods and $34M paid to patient assistance organizations, how much of the GA market is actually viable under current US reimbursement frameworks without heavy manufacturer subsidization?
EMPAVELI Peak Penetration Target
You achieved >5% penetration in C3G/IC-MPGN in a single quarter and have stated a peak target of 50%. How much of the initial demand was a bolus of warehoused patients versus sustainable ongoing incident diagnosis?
Sobi Royalty Cap Mechanics
Following the 90% reduction in Sobi royalty payments, could you provide more clarity on the timeline or projected sales volume required to hit the 1.45x cap and revert back to the 100% royalty rate?